Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the William Blair Biotech Focus Conference 2022 on July 13, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the William Blair Biotech Focus Conference 2022 on July 13, 2022. The company's President and CEO will join a panel discussion titled “AAV Gene Therapy: Delivery and Beyond” at 10:00 am ET. This event focuses on the company's mission to develop and commercialize innovative AAV-based gene therapies for treating monogenic central nervous system diseases. A webcast of the discussion will be available on Taysha's corporate website and archived for 60 days.
Details
News Market Reaction – TSHA
The recorded move for TSHA in the trading session of this news was +8.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and Beyond” panel discussion on Wednesday, July 13, 2022 at 10:00 am ET
DALLAS, July 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a panel discussion on Wednesday, July 13th at the upcoming William Blair Biotech Focus Conference 2022.
A webcast of the event will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
Conference Details:
| Event: | William Blair Biotech Focus Conference 2022 |
| Topic: | AAV Gene Therapy: Delivery and Beyond |
| Date: | Wednesday, July 13, 2022 |
| Time: | 10:00 am ET |
| Format: | Panel Discussion |
| Participants: | Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com
Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.